Checkpoint Inhibitor Changes Take Hold: Approval Standards Stir Debate

Matthew Galsky

Press/Media

Period	16 Feb 2022

Media coverage

1

Media coverage

Title	Checkpoint Inhibitor Changes Take Hold: Approval Standards Stir Debate
Media name/outlet	OncLive
Country/Territory	United States
Date	16/02/22
URL	https://www.onclive.com/view/checkpoint-inhibitor-changes-take-hold-approval-standards-stir-debate
Persons	Matthew Galsky

Related content

Publications & Research Outputs
Association between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer
Research output: Contribution to journal › Letter › peer-review
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Research output: Contribution to journal › Article › peer-review